LSNE tapped for drug substance manufacturing, fill/finish services

By Melissa Fassbender

- Last updated on GMT

LSNE Contract Manufacturing has expanded its relationship with Selecta. (Image: iStock/Tsyhun)
LSNE Contract Manufacturing has expanded its relationship with Selecta. (Image: iStock/Tsyhun)

Related tags Clinical trial

LSNE Contract Manufacturing has signed a manufacturing supply agreement with Selecta Biosciences, Inc. through which the CDMO will advance Selecta’s lead candidate, SEL-212.

The contract development and manufacturing organization (CDMO) has facilities in Bedford and Manchester, NH and specializes in various services, including cGMP fill/finish and lyophilization. 

As part of its agreement with Selecta, LSNE will be providing drug substance manufacturing and fill/finish services.

The services will help Selecta advance its lead program, SEL-212, through the clinic to commercialization.

"We are happy to have LSNE's support as a clinical and commercial manufacturer of SVP-Rapamycin for SEL-212 and future product candidates,​” Lloyd Johnston, Ph.D., Chief Operating Officer of Selecta commented in the press release.

The therapeutic enzyme is designed to be the first biologic treatment for gout, according to the company. A Phase II clinical trial was initiated at the end of October 2016.

FDA inspections

Lyophilization Services of New England, Inc. (LSNE) completed two FDA inspections of its aseptic manufacturing facilities in March​ of this year.

According to the company, the first inspection was an FDA Pre-Approval Inspection (PAI) of its aseptic manufacturing facility in Bedford, NH.  

Following the inspection – which also served as a general GMP inspection – the facility was recommended for approval to manufacture the commercial sterile drug product for US distribution.

The second inspection was a general GMP inspection of LSNE's Harvey Road aseptic manufacturing facility.

Also in March, the company announced​ its acquisition by the private equity firm, Permira.

LSNE did not respond to a request for comment.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Webinars

Headlines